Cite
HARVARD Citation
Gravina, G. et al. (2017). The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma. Journal of hematology & oncology. 10 (1), pp. 1-16. [Online].